vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $151.7M, roughly 1.0× Nutex Health, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 7.8%, a 63.4% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -41.1%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $69.0M).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
NUTX vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $158.6M |
| Net Profit | $11.8M | $112.9M |
| Gross Margin | 30.4% | — |
| Operating Margin | 20.4% | 70.2% |
| Net Margin | 7.8% | 71.2% |
| Revenue YoY | -41.1% | 3661.1% |
| Net Profit YoY | -80.8% | 528.0% |
| EPS (diluted) | $2.34 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | — | ||
| Q3 25 | $267.8M | — | ||
| Q2 25 | $244.0M | — | ||
| Q1 25 | $211.8M | $158.6M | ||
| Q4 24 | $257.6M | $22.6M | ||
| Q3 24 | $78.8M | — | ||
| Q2 24 | $76.1M | — | ||
| Q1 24 | $67.5M | — |
| Q4 25 | $11.8M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $-17.7M | — | ||
| Q1 25 | $21.2M | $112.9M | ||
| Q4 24 | $61.6M | $-10.5M | ||
| Q3 24 | $-8.8M | — | ||
| Q2 24 | $-364.0K | — | ||
| Q1 24 | $-364.0K | — |
| Q4 25 | 30.4% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 51.2% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 27.8% | — | ||
| Q2 24 | 29.7% | — | ||
| Q1 24 | 15.1% | — |
| Q4 25 | 20.4% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | 13.8% | — | ||
| Q1 25 | 38.1% | 70.2% | ||
| Q4 24 | 44.4% | -60.4% | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | 7.8% | — | ||
| Q3 25 | 20.7% | — | ||
| Q2 25 | -7.3% | — | ||
| Q1 25 | 10.0% | 71.2% | ||
| Q4 24 | 23.9% | -46.4% | ||
| Q3 24 | -11.2% | — | ||
| Q2 24 | -0.5% | — | ||
| Q1 24 | -0.5% | — |
| Q4 25 | $2.34 | — | ||
| Q3 25 | $7.76 | — | ||
| Q2 25 | $-2.95 | — | ||
| Q1 25 | $3.33 | $1.90 | ||
| Q4 24 | $11.56 | $-0.15 | ||
| Q3 24 | $-1.72 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $329.4M | $350.1M |
| Total Assets | $918.5M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | — | ||
| Q3 25 | $166.0M | — | ||
| Q2 25 | $96.7M | — | ||
| Q1 25 | $84.7M | $274.8M | ||
| Q4 24 | $40.6M | $128.0M | ||
| Q3 24 | $46.9M | — | ||
| Q2 24 | $40.8M | — | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $329.4M | — | ||
| Q3 25 | $317.2M | — | ||
| Q2 25 | $235.3M | — | ||
| Q1 25 | $176.9M | $350.1M | ||
| Q4 24 | $132.4M | $229.0M | ||
| Q3 24 | $60.4M | — | ||
| Q2 24 | $62.7M | — | ||
| Q1 24 | $63.0M | — |
| Q4 25 | $918.5M | — | ||
| Q3 25 | $964.5M | — | ||
| Q2 25 | $841.0M | — | ||
| Q1 25 | $761.9M | $406.9M | ||
| Q4 24 | $655.3M | $271.6M | ||
| Q3 24 | $438.5M | — | ||
| Q2 24 | $422.4M | — | ||
| Q1 24 | $404.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $131.8M |
| Free Cash FlowOCF − Capex | $69.0M | $131.7M |
| FCF MarginFCF / Revenue | 45.5% | 83.0% |
| Capex IntensityCapex / Revenue | 0.9% | 0.1% |
| Cash ConversionOCF / Net Profit | 5.95× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | — | ||
| Q3 25 | $99.5M | — | ||
| Q2 25 | $27.3M | — | ||
| Q1 25 | $51.0M | $131.8M | ||
| Q4 24 | $54.0K | $-23.2M | ||
| Q3 24 | $6.8M | — | ||
| Q2 24 | $13.3M | — | ||
| Q1 24 | $3.1M | — |
| Q4 25 | $69.0M | — | ||
| Q3 25 | $99.2M | — | ||
| Q2 25 | $26.5M | — | ||
| Q1 25 | $50.9M | $131.7M | ||
| Q4 24 | $-341.0K | $-23.2M | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $12.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 45.5% | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 24.0% | 83.0% | ||
| Q4 24 | -0.1% | -102.7% | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 16.7% | — | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | 1.17× | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
STOK
Segment breakdown not available.
